J&J Bedaquline and the Evolving Role for Accelerated Approval: Confirming Safety, Not Efficacy?
This article was originally published in RPM Report
Discussions during an advisory committee review Janssen’s TB drug bedaquiline showed some interesting thinking around accelerated approval and how much uncertainty can be acceptable—especially when it comes to safety.
You may also be interested in...
Imbalance of deaths for bedaquiline patients despite efficacy on surrogate marker in Phase II study supporting accelerated approval is still unexplained with longer-term data. But with efficacy also still looking good, FDA defends approval for select population with high unmet need.
FDA’s Anti-Infective Drugs Advisory Committee was fully satisfied with “sputum culture conversion” as a surrogate endpoint for accelerated approval, but turned back a last-minute question from FDA on traditional full approval for the tuberculosis drug bedaquiline.
A new FDA designation process for “breakthrough” drugs is one of the few “innovation” features of the FDA Safety & Innovation Act. It is likely to be very attractive to biotech sponsors, though its impact on actual product approvals is uncertain at best. The real “breakthrough,” though, may be in the collaborative model that led to the legislation – and that is an important message for sponsors hoping for bigger reforms ahead.